

Podocarpaside, a Triterpenoid Possessing a New Backbone from *Actaea podocarpa*


Zulfiqar Ali,[†] Shabana I. Khan,[†] Daneel Ferreira,[‡] and Ikhlas A. Khan^{*,†,‡}

National Center for Natural Products Research, and Department of Pharmacognosy,
Research Institute of Pharmaceutical Sciences, School of Pharmacy,
University of Mississippi, Mississippi 38677

ikhlan@olemiss.edu

Received September 6, 2006

ABSTRACT



Podocarpaside (1)

Podocarpaside (1), a novel arabinoside possessing a unique triterpene skeleton was isolated from *Actaea podocarpa*, a closely related species to black cohosh (dietary supplement used for menopausal disorders). Podocarpaside belongs to a new class of triterpenoids, for which the name “ranunculane” is proposed. Compound 1 possesses anticomplement activity.

Actaea, belonging to the family Ranunculaceae, consists of about 28 species distributed throughout East Asia, Europe, and North America.¹ Black cohosh (*A. racemosa*), a rich source of cyclolanostane-type triterpenes,^{2–5} is one of the important *Actaea* species and is used as a dietary supplement for treating menopausal disorders.² It is usually collected from the wild where the risk of adulteration is high due to cogrowth of *A. podocarpa* (summer cohosh), *A. pachypoda* (white cohosh), and *A. rubra* (red cohosh).⁶ As part of our

program aimed at the issues of adulteration, misidentification, and bioequivalence of black cohosh related species in comparison with black cohosh, we reported the isolation and structure elucidation of several *seco*-lanostane- and cyclolanostane-type triterpenes from *A. podocarpa*, *A. pachypoda*, and *A. rubra*.^{7–9} Here, we describe the isolation, the structure determination, and a possible biogenetic origin of the unique structural features of podocarpaside (1), from the roots of *A. podocarpa*.

* Corresponding author. Phone: (1) 662-9157821. Fax: (1) 662-9157989.

[†] National Center for Natural Products Research.

[‡] Department of Pharmacognosy.

(1) Compton, J. A.; Culham, A.; Jury, S. L. *Taxon* **1998**, *47*, 593–634.


(2) Watanabe, K.; Mimaki, Y.; Sakagami, H.; Sashida, Y. *Chem. Pharm. Bull.* **2002**, *50*, 121–125.

(3) Shao, Y.; Harris, A.; Wang, M.; Zhang, H.; Cordell, G.; Bowman, M.; Lemmo, E. *J. Nat. Prod.* **2000**, *63*, 905–910.

(4) Wende, K.; Mugge, C.; Thurow, K.; Schopke, T.; Lindequist, U. *J. Nat. Prod.* **2001**, *64*, 986–989.

(5) Kusano, A.; Shibano, M.; Tsukamoto, D.; Kusano, G. *Chem. Pharm. Bull.* **2001**, *49*, 437–441.

(6) Zerega, N. J. C.; Mori, S.; Lindqvist, C.; Zheng, Q.; Motley, T. J. *Econ. Bot.* **2002**, *56*, 154–164.



The roots of *A. podocarpa* DC. were collected in North Carolina (August 2004) and identified by Mr. Gregory Gust,

William L. Brown Center, Missouri Botanical Garden, Missouri. A voucher specimen has been deposited at the Missouri Botanical Garden. Powdered, freeze-dried roots of *A. podocarpa* (543 g) were extracted with methanol (1.5 L \times 24 h \times 5). The combined extracts were concentrated under reduced pressure to afford colored powder (53.3 g). Part (38.0 g) of this was subjected to vacuum liquid column chromatography over silica gel (600 g) and eluted initially with EtOAc to give three fractions, A (5.0 g), B (6.3 g), and C (0.5 g), and then with methanol to afford fraction D (21.1 g). Fraction B (6.0 g) was divided into 12 fractions (B1–B12) by column chromatography (cc) over reverse-phase silica (RP-18, 300 g, MeOH/H₂O 7:3). Podocarpaside (**1**, 69.3 mg) was obtained by cc from fraction B7 (silica gel, EtOAc/CHCl₃/MeOH/H₂O 15:8:4:1).

Podocarpaside (**1**),¹⁰ [α]_D²⁷ –14.3 (*c* 0.14, MeOH), was obtained as a white powder, which showed a pseudomolecular ion at *m/z* 643 [M + Na]⁺ in the positive ESIMS. The ¹³C NMR spectrum showed 35 signals, which in agreement with HR-ESIMS (found 643.3817, calcd 643.3822 for C₃₅H₅₆NaO₉) led to a molecular formula, C₃₅H₅₆O₉. The HSQC spectrum resolved the 35 carbon signals as 7 methyls, 10 methylenes, 10 methines, and 8 quaternary carbons.

The ¹H NMR spectrum displayed signals for six tertiary methyls [δ _H 1.09 (s, Me-18), 1.21 (s, Me-26, Me-27), 0.93 (s, Me-28), 1.06 (s, Me-29), 0.70 (s, Me-30)], a secondary methyl [δ _H 1.01 (d, *J* = 6.0 Hz, Me-21)], an anomeric methine [δ _H 4.36 (d, *J* = 6.2 Hz, H-1')], and two isolated methylenes [δ _H 1.88/2.17 (each d, *J* = 18.0 Hz, 2H-15); 2.60 (s, 2H-24)]. The ¹³C NMR spectrum of **1** showed two carbonyls [δ _C 219.7 (s, C-16) and 212.2 (s, C-23)], two olefinic carbons [δ _C 133.5 (s, C-9) and 135.1 (s, C-10)], and three oxygenated carbons [δ _C 88.1 (d, C-3), 69.1 (t, C-19), and 70.3 (s, C-25)], in addition to five more oxygenated carbons assignable to α -L-arabinopyranose [δ _C 106.4 (C-1'), 72.8 (C-2'), 74.1 (C-3'), 68.8 (C-4'), and 65.7 (C-5')].^{2,11}

To resolve the overlapping of signals, ¹H NMR spectra of **1** were recorded in acetone-*d*₆, acetone-*d*₆-D₂O, pyridine-*d*₅, pyridine-*d*₅-D₂O,¹² CDCl₃,¹³ CD₃OD, and DMSO-*d*₆ at 400 or 600 MHz (see Supporting Information). Acetone-*d*₆ showed the best resolution, and NMR data recorded in this solvent were utilized for structure elucidation.

The following unambiguous HMBC correlations (in acetone-*d*₆ or pyridine-*d*₅) located the sugar at C-3 [δ _{H/C} 3.31 (H-3)/106.4, 25.2, 15.0, 28.9, 31.7 (C-1', 29, 30, 1, 2); δ _{H/C} 4.36 (H-1')/88.1 (C-3)] and two carbonyls at C-16 and C-23 [δ _{H/C} 1.88, 2.17 (2H-15)/219.7 (C-16); 2.32 (H-17)/219.7

(C-16) and δ _{H/C} 2.45, 3.25 (2H-22)/212.2 (C-23); 2.60 (2H-24)/212.2 (C-23)]. Furthermore, the position of the C₉–C₁₀ double bond and the unique hydroxymethyl at C-11 were revealed by HMBC correlations [H-19a/C-12, 11, 9; H-11/C-8, 9, 10, 13, 19; H-5/C-10; H-12 β /C-9; H-1 β /C-9, 10; H-2 α /C-10; and H-7 β /C-9]. Detailed HMBC associations are shown in Figure 2. Analysis of the ¹H–¹H COSY spectrum led to partial structures (Figure 1), which were




Figure 1. Partial structures of **1**.

connected by using HMBC correlations (Figure 2). The NMR assignments (Table 1) were done by analyzing ¹H–¹H COSY




Figure 2. Unambiguous HMBC correlations of **1**.

(Figure 1), HSQC, HMQC, 2D *J*-resolved, HMBC (Figure 2), and ROESY (Figure 3) spectra.

The coupling constants of H-3 (*J* = 4.8, 11.6 Hz) revealed its axial α -orientation and ultimately equatorial β -oriented 3-hydroxylation. Assuming a β -oriented 3-hydroxylation and hence 3*S*-absolute confirmation, we defined the configuration of the remaining stereogenic carbon atoms from the observed

(7) Ali, Z.; Khan, S. I.; Fronczek, F. R.; Khan, I. A. *Phytochemistry* **2006**, in press.

(8) Ali, Z.; Khan, S. I.; Fronczek, F. R.; Khan, I. A. *J. Nat. Prod.* **2006**, accepted.

(9) Ali, Z.; Khan, S. I.; Khan, I. A. *Planta Med.* **2006**, published online.

(10) Podocarpaside (**1**). White powder; [α]_D²⁷ –14.3 (*c* 0.14, MeOH); IR (KBr) ν _{max} 3380, 2939, 1731, 1652 cm⁻¹; NMR, see Table 1; positive ESIMS *m/z* 643 [M + Na]⁺; HR-ESIMS found 643.3817, calcd for C₃₅H₅₆NaO₉ 643.3822.

(11) Chen, S.; Fabricant, D. S.; Lu, Z. Z.; Fong, H. H. S.; Farnsworth, N. R. *J. Nat. Prod.* **2002**, *65*, 1391–1397.

(12) ¹H NMR (C₅D₅N–D₂O, 600 MHz) δ _H 4.76 (d, *J* = 7.2 Hz, H-1'), 4.37 (dd, *J* = 7.2, 8.8 Hz, H-2'), 4.18 (dd, *J* = 3.6, 8.8 Hz, H-3'), 4.32 (br s, H-4'), 4.21 (dd, *J* = 3.2, 11.2 Hz, H-5' β), 3.71 (overlap, H-5' α).


(13) ¹³C NMR (CDCl₃, 600 MHz) δ _C 28.2 (C-1), 30.6 (C-2), 88.1 (C-3), 41.1 (C-4), 48.1 (C-5), 23.2 (C-6), 25.2 (C-7), 41.2 (C-8), 132.2 (C-9), 134.5 (C-10), 37.9 (C-11), 31.7 (C-12), 45.2 (C-13), 42.3 (C-14), 48.9 (C-15), 220.0 (C-16), 60.9 (C-17), 17.8 (C-18), 68.4 (C-19), 27.2 (C-20), 21.0 (C-21), 50.8 (C-22), 213.0 (C-23), 53.6 (C-24), 70.1 (C-25), 29.5 (C-26), 29.6 (C-27), 18.9 (C-28), 24.7 (C-29), 14.7 (C-30), 105.3 (C-1'), 73.0 (C-2'), 71.7 (C-3'), 68.2 (C-4'), 65.6 (C-5'); ¹H NMR (CDCl₃, 600 MHz, most of the signals appeared broad) δ _H 4.36 (br d, *J* = 5.4 Hz, H-1'), 3.91 (br, H-4', H-5'e), 3.72 (br, H-2'), 3.67 (br, H-3'), 3.53 (overlap, H-5'a, H-19a), 3.47 (br, H-19b), 3.30 (br, H-3), 3.21 (br d, *J* = 13.8 Hz, H-22a), 2.71 (br d, *J* = 13.2 Hz, H-1 β), 2.66 (d, *J* = 18.0 Hz, H-24a), 2.56 (d, *J* = 18.0 Hz, H-24b), 2.34 (br overlap, H-8, H-21, H-22b), 2.19 (d, *J* = 8.4 Hz, H-17), 2.17 (br d, *J* = 14.4 Hz, H-12 β), 2.11 (d, *J* = 17.7 Hz, H-15 β), 2.04 (br, H-2 β), 1.92 (d, *J* = 17.7 Hz, H-15 α), 1.88 (br, H-6 β), 1.84 (br, H-12 α), 1.78 (br, H-5), 1.74 (br, H-1 α), 1.52 (m, H-2 α), 1.43 (br, H-7 β), 1.25 (s, 3H-27), 1.23 (s, 3H-26), 1.22 (overlap, H-6 α , H-7 α), 1.07 (s, 3H-18), 1.01 (br overlap, 3H-21, 3H-29), 0.88 (s, 3H-28), 0.68 (s, 3H-30).

Table 1. NMR Data of Podocarpaside (1)


no.	δ_C^a (δ_C^b) (mult)	δ_H^a (mult., J , Hz)	δ_H^b (mult., J , Hz)
1 α	28.9 (29.0) t	1.72 (m)	1.83 (overlap)
1 β		2.77 (br d, 13.6)	2.89 (br d, 8.4)
2 α	31.7 (31.8) t	2.02 (m)	2.33 (m)
2 β		1.52 (m)	1.83 (overlap)
3 α	88.1 (88.0) d	3.31 (dd, 4.8, 11.6)	3.56 (dd, 3.8, 11.0) ^c
4	42.0 (41.9) s		
5 α	49.1 (48.9) d	1.93 (m)	1.91 (overlap)
6 α	24.1 (23.9) t	1.75 (m)	1.72 (m)
6 β		1.32 (m)	1.21 (overlap)
7 α	26.2 (26.0) t	1.29 (m)	1.21 (overlap)
7 β		1.47 (m)	1.34 (m)
8 β	42.2 (41.9) d	2.42 (overlap)	2.38 (overlap)
9	133.5 (133.3) s		
10	135.1 (134.9) s		
11 α	39.3 (39.5) d	3.10 (br m)	3.33 (br m)
12 α	32.1 (32.2) t	1.82 (dd, 8.8, 14.4)	1.93 (overlap)
12 β		2.37 (br d, 14.4)	2.71 (d, 13.2) ^c
13	46.1 (45.9) s		
14	43.1 (42.9) s		
15 α	49.5 (49.5) t	1.88 (d, 18.0)	1.99 (d, 18.0)
15 β		2.17 (d, 18.0)	2.22 (d, 18.0)
16	219.7 (219.9) s		
17 α	61.6 (61.6) d	2.32 (d, 9.0) ^c	2.41 (d, 8.4)
18	18.2 (18.3) q	1.09 (s)	1.16 (s)
19a	69.1 (68.9) t	3.45 (dd, 6.0, 11.0)	3.82 (overlap)
19b		3.49 (dd, 6.0, 11.0) ^c	
20	28.1 (28.1) d	2.32 (overlap)	2.64 (m)
21	21.2 (21.4) q	1.01 (d, 6.0)	1.15 (d, 6.6)
22a	51.6 (51.8) t	2.45 (dd, 8.4, 17.0)	2.69 (dd, 8.4, 17.0) ^c
22b		3.25 (dd, 1.6, 17.0)	3.56 (dd, 3.0, 17.0) ^c
23	212.2 (211.4) s		
24a	55.4 (56.4) t	2.60 (s)	2.80 (d, 15.0)
24b		2.60 (s)	2.83 (d, 15.0)
25	70.3 (70.1) s		
26	30.1 (30.6) q	1.21 (s)	1.48 (s)
27	30.3 (30.9) q	1.21 (s)	1.47 (s)
28	19.1 (19.2) q	0.93 (s)	0.90 (s)
29	25.2 (25.4) q	1.06 (s)	1.31 (s)
30	15.0 (15.3) q	0.70 (s)	0.88 (s)
1'a			
x	106.4 (107.5) d	4.36 (d, 6.2)	4.78 (d, 6.9)
2'eq	72.8 (73.4) d	3.64 (dd, 6.2, 8.2)	4.41 (dd, 6.9, 8.4)
3'a			
x	74.1 (75.1) d	3.57 (dd, 3.2, 8.2)	4.16 (dd, 2.4, 8.4)
4'eq	68.8 (69.9) d	3.81 (br s)	4.32 (br s)
5'a			
x	65.7 (67.1) t	3.52 (dd, 3.2, 12.0)	3.78 (dd, 2.4, 12.0) ^c
5'eq		3.82 (dd, 3.6, 12.0)	4.27 (br d, 12.0)

^a Data were recorded in C₃D₆O at 400 MHz and in C₅D₅N at 600 MHz. ^b Chemical shifts (δ) are in ppm. ^c Coupling constants were recorded on a 2D J -resolved spectrum.

ROESY associations (Figure 3). Thus, H-3 α shows association with H-5 α , H-5 α with H-7 α , H-7 α with Me-28 α , and Me-28 α with H-17 α . The latter association then indicates a β -orientation of the C-17 side chain. H-20 associates strongly with Me-18 and hence confirms the β -orientation of this methyl group. Finally, Me-18 shows association with both H-8 and the C-19 oxymethylene protons to confirm the β -orientation of these groups. These associations then permit

**Figure 3.** ROESY correlations of 1.

definition of the absolute configuration of podocarpaside as 3*S*, 5*R*, 8*S*, 11*S*, 13*R*, 14*S*, and 17*R*. The 20*R* absolute configuration is assumed on the basis of the predominance of 20*S*-configured naturally occurring lanostane-type triterpenes.¹⁴ Note that the spatial arrangement of the substituents at C-20 in podocarpaside is the same as that for 20*S*-configured lanostane-type triterpenes.¹⁴ The configuration is inverted because of a reversal of Cahn–Ingold–Prelog sequencing. The β -oriented C-11 hydroxymethyl group, based on the β -position of the cyclopropyl moiety in the cycloartane skeleton,^{2–5} is also supported by the proposed biogenetic pathway (Figure 4). The sugar obtained after

**Figure 4.** Proposed biogenetic pathway for podocarpaside.

standard acid hydrolysis was identified as L-arabinose by comparing its TLC (EtOAc–CHCl₃–MeOH–H₂O 12:8:8:4) and specific rotation [α]_D²⁸ +102.8 (*c* 0.51, H₂O) with a reference sample of L-arabinose purchased from Sigma-Aldrich. On the basis of these spectroscopic data, compound **1** was defined as 3 β ,19,25-trihydroxy-16,23-dioneranuncul-9(10)-ene 3-*O*- α -L-arabinopyranoside.

Podocarpaside belongs to a new class of triterpenoids, for which the name “ranunculane” is proposed. It probably originates from a cycloartane precursor (**2**) by initial oxygenation of the α -equatorial C-11 hydrogen (Figure 4). The α -alcohol (**3**) is then susceptible to acid-catalyzed rearrangement of the strained cyclopropane into cyclobutane analogue **4**. Hydrolytic ring cleavage then affects the equivalent of the methyl migration and generation of the C₉–C₁₀ double bond. The lanostane and its rearranged classes of triterpenoids are shown in Figure 5.




Figure 5. Lanostane and its rearranged classes.

Podocarpaside was tested for cytotoxicity toward mammalian kidney fibroblasts (Vero) and epithelial (LLC-PK₁) cells and for anticancer activity in a panel of human solid tumor cells (SK-MEL, KB, BT-549, and SK-OV-3) in an assay described earlier.¹⁵ The compound was not cytotoxic to kidney cells up to 40 μ M. It did not exhibit any estrogenic

effect up to 500 μ M, in a cell-based assay.¹⁶ No antioxidant activity was observed up to 30 μ M in HL-60 cells by a DCFH-DA assay.¹⁷ However, it inhibited Human Complement activity with an IC₅₀ value of 190 μ M in an in vitro assay using sensitized RBCs and human serum.⁷ Ursolic acid and oleanolic acid were used as positive controls showing IC₅₀ values of 54 and 80 μ M, respectively. The anticomplement activity of some triterpenes has been reported earlier with IC₅₀ values in the range of 101–180 μ M.¹⁸ The Human Complement System (HCS) is an integral part of the body’s immune response against infections, but it may cause adverse effects when activated inappropriately. Activation of HCS is known to be initiated by a number of agents such as pathogens, foreign molecules, and immune complexes. Therefore, the modulation of complement activity becomes important under pathological conditions of inflammation and during organ transplantation.^{18,19}

Acknowledgment. This work was supported by grants from the United States Food and Drug Administration (FDA) (no. FD-U-002071-01) and the United States Department of Agriculture (USDA) (no. 58-6408-2-0009). We would like to thank Mr. James S. Miller, Mr. Wendy Applequist, Mr. Gregory Gust, Mr. John Stone, and Mr. Leith Nye from the Missouri Botanical Garden for providing the plant material and Mr. Peter and Mr. Frank for conducting NMR experiments.

Supporting Information Available: ¹H NMR spectra of podocarpaside (**1**) in acetone-*d*₆, acetone-*d*₆-D₂O, pyridine-*d*₅, pyridine-*d*₅-D₂O, CDCl₃, CD₃OD, and DMSO-*d*₆; and ¹³C and 2D NMR spectra in acetone-*d*₆ and pyridine-*d*₅. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL062212S

(14) Li, Y.; Ishibashi, M.; Satake, M.; Chen, X.; Oshima, Y.; Ohizumi, Y. *J. Nat. Prod.* **2003**, *66*, 696–698.

(15) Mustafa, J.; Khan, S. I.; Ma, G.; Walker, L. A.; Khan, I. A. *Lipids* **2004**, *39*, 659–666.

(16) Tabanca, N.; Khan, S. I.; Bedir, E.; Annavarapu, S.; Willett, K.; Khan, I. A.; Kirimer, N.; Baser, K. H. *Planta Med.* **2004**, *70*, 728–735.

(17) Takamatsu, S.; Galal, A. M.; Ross, S. A.; Ferreira, D.; Elsohly, M. A.; Ibrahim, A. R.; El-Ferally, F. S. *Phytother. Res.* **2003**, *17*, 963–966.

(18) Lee, S.; Park, J.; Lee, Y.; Lee, C.; Min, B.; Kim, J.; Lee, H. *Biol. Pharm. Bull.* **2004**, *27*, 1883–1886.

(19) Master, H. E.; Khan, S. I.; Poojari, K. A. *Bioorg. Med. Chem.* **2005**, *13*, 4891–4899.